Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock Holdings Boosted by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lifted its position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 27.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 97,276 shares of the company’s stock after acquiring an additional 20,916 shares during the period. Allspring Global Investments Holdings LLC owned 0.22% of Voyager Therapeutics worth $821,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Armistice Capital LLC lifted its holdings in Voyager Therapeutics by 15.3% in the third quarter. Armistice Capital LLC now owns 4,178,000 shares of the company’s stock worth $32,380,000 after purchasing an additional 554,000 shares during the period. Bank of New York Mellon Corp lifted its holdings in Voyager Therapeutics by 0.8% in the third quarter. Bank of New York Mellon Corp now owns 192,869 shares of the company’s stock worth $1,495,000 after purchasing an additional 1,455 shares during the period. TD Asset Management Inc lifted its holdings in Voyager Therapeutics by 100.0% in the third quarter. TD Asset Management Inc now owns 133,502 shares of the company’s stock worth $1,035,000 after purchasing an additional 66,751 shares during the period. Kestra Advisory Services LLC acquired a new stake in Voyager Therapeutics in the third quarter worth about $980,000. Finally, Massachusetts Financial Services Co. MA acquired a new stake in Voyager Therapeutics in the third quarter worth about $887,000. Institutional investors own 48.03% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on VYGR. StockNews.com raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 9th. Citigroup assumed coverage on shares of Voyager Therapeutics in a report on Thursday, March 7th. They issued a “buy” rating and a $16.00 price target for the company. Wells Fargo & Company raised shares of Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $9.00 to $14.00 in a report on Tuesday, January 2nd. Guggenheim assumed coverage on shares of Voyager Therapeutics in a report on Tuesday, March 26th. They issued a “buy” rating and a $22.00 price target for the company. Finally, HC Wainwright assumed coverage on shares of Voyager Therapeutics in a report on Tuesday, March 19th. They issued a “buy” rating and a $30.00 price target for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Voyager Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $19.33.

Voyager Therapeutics Trading Down 1.0 %

VYGR stock opened at $7.57 on Thursday. Voyager Therapeutics, Inc. has a one year low of $6.06 and a one year high of $14.34. The firm has a market capitalization of $411.06 million, a PE ratio of 2.45 and a beta of 0.96. The firm has a 50-day moving average of $8.80 and a two-hundred day moving average of $7.97.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $1.25 EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $1.84. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. The company had revenue of $90.06 million during the quarter, compared to analyst estimates of $4.95 million. On average, equities research analysts anticipate that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.